Eton Pharmaceutical ETON
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 85th percentile, 5-year average -71.9x
#2448 of 2994 stocks by PE (1 = cheapest)
Near the top of its 5-year range · 80th percentile, 5-year average 13.6x
#5157 of 5335 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 93rd percentile, 5-year average 6.5x
#4601 of 5159 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 21.21 | – | 13.55 | 80% (pricier than usual) | #5157 of 5335 (1 = cheapest) |
| PE | 41.51 | 21.78 | -71.90 | 85% (pricier than usual) | #2448 of 2994 (1 = cheapest) |
| PS | 13.07 | 6.81 | 6.51 | 93% (pricier than usual) | #4601 of 5159 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on ETON.
Sign in to join the discussion.